The Pentagon wants ketamine wafers as a battlefield medicine option
BLUF – The Pentagon awarded a nearly $41 million contract to Singapore-based iX Biopharma to develop Wafermine, a sublingual ketamine wafer for treating moderate to severe battlefield pain, with the manufacturer pursuing emergency use authorization that could allow military deployment before full FDA approval. For Navy Medicine, this needle-free alternative to injectable ketamine could expand pain management options for corpsmen treating combat casualties in austere environments, although its clinical effectiveness, safety and regulatory status must be established before widespread use.